Researchers
-
Alba Oliveras
Cardiovascular clinical research
-
Anna Contra Carne
Cardiovascular clinical research
-
Antonio Carol Ruiz
Cardiovascular clinical research
-
Antonia Ortega Díaz
Cardiovascular clinical research
-
Carlos Enrique Sabbagh Fajardo
Cardiovascular clinical research
-
carmen martin
Cardiovascular clinical research
-
Elizabeth Mena Sebastià
Cardiovascular clinical research
-
Joan Pol Monteys Montblanch
Cardiovascular clinical research
-
José Navarrete Monte
Cardiovascular clinical research
-
Maria Del Señor Cortés Fernández
Cardiovascular clinical research
-
Marta Camprecios Crespo
Cardiovascular clinical research
-
Mercè Faraudo
Cardiovascular clinical research
-
Miriam Garcia Bermudez
Cardiovascular clinical research
-
Olga Guri
Cardiovascular clinical research
-
Peter Castellanos
Cardiovascular clinical research
-
Pilar Sánchez Chamero
Cardiovascular clinical research
Phd -
Raúl Lafuente Masqueda
Cardiovascular clinical research
-
Román Freixa Pamías
Cardiovascular clinical research
Phd -
Sandra Lara Sanmartin
Cardiovascular clinical research
Contact the group
Form
Projects
-
Cardiovascular clinical research
Researcher
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of dapagliflozin 10 mg once a day on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes,
-
DISTRICT ATTORNEY:
ActraZeneca AB
-
TYPE E:
RD2004
-
Cardiovascular clinical research
Researcher
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Multicenter, randomized, double-blind, event-based study comparing the efficacy and safety of oral rivaroxaban with placebo in reducing the risk of death, myocardial infarction, or stroke in patients with chronic heart failure and significant coronary artery disease after a hospitalization for exacerbation of heart failure,
-
DISTRICT ATTORNEY:
Janssen-Cilag International NV
-
TYPE E:
RD2004
-
Cardiovascular clinical research
Researcher
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Multicenter, randomized, double-blind, parallel-group study of active control, to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in patients with heart failure (Class II-IV NYHA) with preserved ejection fraction,
-
DISTRICT ATTORNEY:
Novartis Pharmaceutica SA
-
TYPE E:
RD2004
-
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Multicenter, randomized, double-blind, event-based study comparing the efficacy and safety of oral rivaroxaban with placebo in reducing the risk of death, myocardial infarction, or stroke in patients with chronic heart failure and significant coronary artery disease after a hospitalization for exacerbation of heart failure,
-
DISTRICT ATTORNEY:
Janssen-Cilag International NV
-
TYPE E:
RD2004
-
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Multicenter, randomized, double-blind, parallel-group study of active control, to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in patients with heart failure (Class II-IV NYHA) with preserved ejection fraction,
-
DISTRICT ATTORNEY:
Novartis Pharmaceutica SA
-
TYPE E:
RD2004
-
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of dapagliflozin 10 mg once a day on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes,
-
DISTRICT ATTORNEY:
ActraZeneca AB
-
TYPE E:
RD2004
Lines of action
- Self control in carriers Mechanical prosthesis
- Cryptogenetic stroke
- Spontaneous coronary dissection
- Atrial fibrillation, anticoagulation and stroke / bleeding
- Integrated cardiology primary care
- LDL control in post-SCA patients
- Impact of IC Functional Unit on Hospital Admissions / Re-admissions
